SKYE BIOSCIENCE, INC. COMMON STOCK
NASDAQ: SKYE (Skye Bioscience, Inc.)
Kemas kini terakhir: 50 minit lalu2.04
-0.04 (-1.92%)
| Penutupan Terdahulu | 2.08 |
| Jumlah Dagangan | 66,179 |
| Harga / Buku (P/B) | 1.96 |
| Julat 52 Minggu |
| EPS Cair (TTM) | -0.830 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.70% |
| Nisbah Semasa (MRQ) | 11.85 |
| Aliran Tunai Operasi (OCF TTM) | -29.71 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -14.01 M |
| Pulangan Atas Aset (ROA TTM) | -28.04% |
| Pulangan Atas Ekuiti (ROE TTM) | -47.27% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Skye Bioscience, Inc. | Bercampur | Bercampur |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -2.5 |
| Purata | -1.50 |
|
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 1.44% |
| % Dimiliki oleh Institusi | 80.76% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| 5Am Venture Management, Llc | 30 Jun 2026 | 1,210,220 |
| Versant Venture Management, Llc | 30 Jun 2026 | 250,963 |
| Sphera Funds Management Ltd. | 30 Jun 2026 | 84,866 |
| Platinum Investment Management Ltd | 30 Jun 2026 | 29,137 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |